CN104822378A - 作为糖尿病的生物标志物的cmpf和相关方法 - Google Patents

作为糖尿病的生物标志物的cmpf和相关方法 Download PDF

Info

Publication number
CN104822378A
CN104822378A CN201380060932.9A CN201380060932A CN104822378A CN 104822378 A CN104822378 A CN 104822378A CN 201380060932 A CN201380060932 A CN 201380060932A CN 104822378 A CN104822378 A CN 104822378A
Authority
CN
China
Prior art keywords
cmpf
level
methods
experimenter
impaired glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380060932.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·惠勒
K·普伦蒂塞
戴菲寒
R·雷特纳卡兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of CN104822378A publication Critical patent/CN104822378A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380060932.9A 2012-09-21 2013-09-20 作为糖尿病的生物标志物的cmpf和相关方法 Pending CN104822378A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261703867P 2012-09-21 2012-09-21
US61/703,867 2012-09-21
US201361787718P 2013-03-15 2013-03-15
US61/787,718 2013-03-15
PCT/CA2013/000798 WO2014043793A1 (en) 2012-09-21 2013-09-20 Cmpf as a biomarker for diabetes and associated methods

Publications (1)

Publication Number Publication Date
CN104822378A true CN104822378A (zh) 2015-08-05

Family

ID=50340483

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380060932.9A Pending CN104822378A (zh) 2012-09-21 2013-09-20 作为糖尿病的生物标志物的cmpf和相关方法

Country Status (8)

Country Link
US (1) US9726659B2 (enExample)
EP (1) EP2897614A4 (enExample)
CN (1) CN104822378A (enExample)
BR (1) BR112015006284A2 (enExample)
CA (1) CA2885416A1 (enExample)
IN (1) IN2015DN02868A (enExample)
MX (1) MX2015003642A (enExample)
WO (1) WO2014043793A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109765360A (zh) * 2018-12-12 2019-05-17 杭州博谱医药科技有限公司 Cmpf均相酶免疫检测试剂盒、制备方法及检测方法
CN110007092A (zh) * 2019-04-08 2019-07-12 杭州博谱医药科技有限公司 一种胶乳微球-蛋白-cmpf偶联物及其制备方法以及测定血清中cmpf含量的试剂盒
CN110187123A (zh) * 2019-05-06 2019-08-30 天津医科大学总医院 一种糖尿病早期诊断生物标志物及其应用
CN114924011A (zh) * 2022-06-30 2022-08-19 重庆大学附属肿瘤医院 高效液相色谱串联质谱法检测血浆中cmpf含量的方法
CN116568345A (zh) * 2020-11-13 2023-08-08 费森尤斯医疗保健控股公司 增加红细胞计数的技术
CN117338776A (zh) * 2019-01-23 2024-01-05 醣解生医股份有限公司 β-内酰胺类化合物或其盐用于长效预防或治疗葡萄糖代谢失调的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019624B1 (en) 2013-07-09 2020-09-16 Stemina Biomarker Discovery, Inc. Biomarkers of autism spectrum disorder
CN107205699A (zh) * 2015-02-11 2017-09-26 西门子公司 用于无创地检查至少血液成分的部分的装置和方法以及装置的应用
CN104678016B (zh) * 2015-02-11 2017-05-03 浙江中烟工业有限责任公司 一种采用高效液相色谱测定苯并芘在吸烟后大鼠肺部沉积量的方法
WO2016145532A1 (en) * 2015-03-16 2016-09-22 The Governing Council Of The University Of Toronto Cmpf for the treatment or prevention of hepatic steatosis
WO2018042072A1 (en) * 2016-09-02 2018-03-08 Afekta Technologies Oy Furan fatty acid biomarkers of nutritional status
EP4385508A1 (en) * 2022-12-16 2024-06-19 Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD) Furan fatty acids for enhancing muscle mass

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546649B1 (en) 2007-11-02 2015-02-25 Metabolon Inc. Biomarkers for fatty liver disease and methods using the same
WO2010045180A1 (en) 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
US8206591B2 (en) * 2008-10-16 2012-06-26 Fresenius Medical Care Holdings, Inc. Method of removing protein-bound deleterious substances during extracorporeal renal replacement treatment
WO2011146683A1 (en) 2010-05-19 2011-11-24 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
WO2012015904A2 (en) 2010-07-28 2012-02-02 Metabolon, Inc. Biomarkers for prostate cancer and methods using the same
US20140303228A1 (en) 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
WO2013086365A2 (en) * 2011-12-09 2013-06-13 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109765360A (zh) * 2018-12-12 2019-05-17 杭州博谱医药科技有限公司 Cmpf均相酶免疫检测试剂盒、制备方法及检测方法
CN117338776A (zh) * 2019-01-23 2024-01-05 醣解生医股份有限公司 β-内酰胺类化合物或其盐用于长效预防或治疗葡萄糖代谢失调的用途
CN110007092A (zh) * 2019-04-08 2019-07-12 杭州博谱医药科技有限公司 一种胶乳微球-蛋白-cmpf偶联物及其制备方法以及测定血清中cmpf含量的试剂盒
CN110187123A (zh) * 2019-05-06 2019-08-30 天津医科大学总医院 一种糖尿病早期诊断生物标志物及其应用
CN110187123B (zh) * 2019-05-06 2022-07-22 天津医科大学总医院 一种糖尿病早期诊断生物标志物及其应用
CN116568345A (zh) * 2020-11-13 2023-08-08 费森尤斯医疗保健控股公司 增加红细胞计数的技术
CN114924011A (zh) * 2022-06-30 2022-08-19 重庆大学附属肿瘤医院 高效液相色谱串联质谱法检测血浆中cmpf含量的方法
CN114924011B (zh) * 2022-06-30 2023-08-25 重庆大学附属肿瘤医院 高效液相色谱串联质谱法检测血浆中cmpf含量的方法

Also Published As

Publication number Publication date
CA2885416A1 (en) 2014-03-27
US9726659B2 (en) 2017-08-08
BR112015006284A2 (pt) 2017-07-04
WO2014043793A1 (en) 2014-03-27
EP2897614A1 (en) 2015-07-29
EP2897614A4 (en) 2016-04-13
IN2015DN02868A (enExample) 2015-09-11
MX2015003642A (es) 2016-07-11
US20150247839A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
US9726659B2 (en) CMPF as a biomarker for diabetes and associated methods
Yang et al. Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells
Suga et al. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
Abu‐Farha et al. ANGPTL8 (betatrophin) role in diabetes and metabolic diseases
Király et al. Swim training prevents hyperglycemia in ZDF rats: mechanisms involved in the partial maintenance of β-cell function
Kleinert et al. Quantitative proteomic characterization of cellular pathways associated with altered insulin sensitivity in skeletal muscle following high-fat diet feeding and exercise training
Dixit et al. Effects of CaMKII-mediated phosphorylation of ryanodine receptor type 2 on islet calcium handling, insulin secretion, and glucose tolerance
EP2854865B1 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
Wang et al. Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single‐Center, Retrospective Case‐Control Study
Liao et al. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients
Reutrakul et al. Lower nocturnal urinary 6-sulfatoxymelatonin is associated with more severe insulin resistance in patients with prediabetes
JP2015520378A (ja) 糖尿病バイオマーカ
Urbano et al. Altered expression of uncoupling protein 2 in GLP-1-producing cells after chronic high glucose exposure: implications for the pathogenesis of diabetes mellitus
Ni et al. Proper mTORC1 activity is required for glucose sensing and early adaptation in human pancreatic β cells
Tseng et al. Pharmacological and mechanistic study of PS1, a Pdia4 inhibitor, in β-cell pathogenesis and diabetes in db/db mice
Li et al. Calcium/calmodulin dependent protein kinase IV in trophoblast cells under insulin resistance: Functional and metabolomic analyses
He et al. Transthyretin contributes to insulin resistance and diminishes exercise-induced insulin sensitivity in obese mice by inhibiting AMPK activity in skeletal muscle
Hall et al. Amyloid beta 42 alters cardiac metabolism and impairs cardiac function in male mice with obesity
Elkin et al. Exposure to trichloroethylene metabolite S-(1, 2-Dichlorovinyl)-l-cysteine causes compensatory changes to macronutrient utilization and energy metabolism in placental HTR-8/SVneo cells
Gao et al. Oxidative stress increases the risk of pancreatic β cell damage in chronic renal hypertensive rats
WO2012116074A1 (en) Biomarkers of insulin sensitivity
EP3155433B1 (en) A novel soluble biomarker for insulin resistance
Lee et al. Serum preadipocyte factor 1 concentrations and risk of developing diabetes: a nested case–control study
Wilkerson-Vidal et al. Young adult male LEW. 1WR1 rats have reduced beta cell area and develop glucose intolerance
Wang et al. Dynamic multi-omics profiling of islet and gut hormonal secretion and peripheral crosstalk in response to various nutrient loads

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150805